Welcome to our dedicated page for Nexentis Technologies SEC filings (Ticker: NXTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nexentis Technologies Inc. filings document material events, stockholder voting matters, capital-structure changes, and Nasdaq-related approvals for the company’s common stock. Its recent Form 8-K disclosures include amendments affecting security-holder rights and the completed one-for-seven reverse stock split of the company’s common stock.
The company’s proxy materials describe proposals for reverse stock split authority and equity issuance approvals under Nasdaq Marketplace Rule 5635(d). Other filing categories include material agreements, capital-structure disclosure, board authority, quorum and voting results, and amendments to the company’s governing documents.
Nexentis Technologies Inc. (NXTS) has been notified by Nasdaq that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing under Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 of stockholders’ equity. Nexentis reported $1,782,000 of stockholders’ equity as of June 30, 2026 in its Form 10‑Q.
The notice does not immediately affect trading of Nexentis common stock on The Nasdaq Capital Market. The company has 45 days, until October 15, 2026, to submit a plan to regain compliance. If Nasdaq accepts the plan, Nexentis may receive up to a 180‑day extension through February 27, 2027 to restore compliance. If a plan is not accepted or compliance is not regained, Nasdaq staff would issue a delisting determination, which Nexentis could appeal to a Nasdaq Hearings Panel, staying any delisting while the appeal is pending.
Nexentis Technologies Inc., a Nevada-based company with oncology (MitoCareX) and renewable energy (NITO/solar JV) activities, reported a net loss of $17.7 million for the six months ended June 30, 2026, compared with $5.8 million a year earlier. Results include a $6.3 million non-cash goodwill impairment on the MitoCareX reporting unit and financing expenses of $8.9 million, largely linked to fair value changes in warrant and credit facility liabilities.
Total assets were $18.7 million, with cash, cash equivalents and restricted cash of $7.7 million. Total liabilities rose to $16.9 million, driven by warrant-related liabilities and contingent considerations, leaving total stockholders’ equity at $1.8 million. The company has an accumulated deficit of about $56.3 million and states there is substantial doubt about its ability to continue as a going concern, expecting continued losses and negative operating cash flows.
To fund operations, Nexentis raised capital via a standby equity purchase, June 2026 registered direct offerings and related PIPE warrants, and expanded a credit facility with Pure Capital that includes a large warrant position accounted for as a liability. It also completed a 1-for-7 reverse stock split and deconsolidated its former Save Foods business, recording an $0.9 million gain in discontinued operations and receiving Voice Assist shares now measured at fair value.
Nexentis Technologies Inc. changed its external auditor. On August 6, 2026, the board and audit committee dismissed Somekh Chaikin, a member firm of KPMG International (“KPMG Israel”), as the company’s independent registered public accounting firm and appointed Brightman Almagor Zohar & Co., a firm in the Deloitte Global Network (“Deloitte Israel”), to audit the consolidated financial statements for the year ended December 31, 2026.
KPMG Israel’s reports for the years ended December 31, 2025 and 2024 contained an explanatory paragraph stating that Nexentis had suffered recurring losses from operations and had a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. The company states there were no disagreements or reportable events with KPMG Israel under Regulation S‑K Items 304(a)(1)(iv) and (v), and KPMG Israel provided a letter (Exhibit 16.1) agreeing with these statements.
An amended Schedule 13G for Nexentis Technologies Inc. reports that individual investor Eun Young Lee, a citizen of the Republic of Korea, beneficially owns 47,000 shares of the company’s common stock. This represents 3.23% of the class, calculated using 1,453,333 shares outstanding as of June 23, 2026, as referenced from a prospectus supplement.
Lee has sole voting and sole dispositive power over all 47,000 shares, with no shared voting or dispositive power. The report is characterized as ownership of 5 percent or less of Nexentis’s common stock.
Nexentis Technologies Inc. filed a resale registration covering up to 2,572,874 shares of common stock for existing investors. The shares are issuable upon exercise of three warrant classes: 311,876 First PIPE Warrants, 410,998 Second PIPE Warrants, and 1,850,000 Facility Warrant shares. Nexentis will not receive proceeds from selling stockholder resales, but could receive up to $6.0 million in gross proceeds if all warrants are exercised for cash; the warrants also allow cashless exercise in some circumstances.
Shares outstanding were 1,453,333 as of July 10, 2026, and would rise to 4,026,207 if all registered warrants are exercised. The company operates in biotechnology through wholly owned MitoCareX Bio Ltd., developing small-molecule therapies targeting mitochondrial SLC25A proteins for cancers such as non-small cell lung and pancreatic cancer, and in solar energy via a 70% interest in an Italian PV project joint venture. For 2025, Nexentis reported a net loss attributable to stockholders of $4.0 million and total basic loss per share of $24.71. Auditors highlighted substantial doubt about its ability to continue as a going concern. The company also has a EUR 10,000,000 credit facility with 7% interest tied to the issuance of the Facility Warrant.
Nexentis Technologies Inc. filed a post-effective amendment to its Form S‑3 shelf registration, keeping in place the ability to offer up to $100,000,000 of common stock, preferred stock, debt securities, warrants, subscription rights and units. The amendment primarily updates incorporated information, including historical financial statements and unaudited pro forma data for the acquisition of MitoCareX Bio Ltd., and does not register additional securities.
As of July 5, 2026, shares of common stock outstanding were 1,453,333, of which 1,396,490 were held by non‑affiliates, giving an aggregate non‑affiliate market value of $18,154,370 under General Instruction I.B.6 of Form S‑3. Nexentis states it has not sold securities under this instruction in the prior 12‑month period and remains subject to the one‑third cap relative to this market value.
The company is repositioned around biotechnology and renewable energy, led by wholly owned subsidiary MitoCareX, which develops small‑molecule cancer and inflammatory metabolic disease therapeutics using its MITOLINE™ structural biology platform, and a 70% interest in an Italian solar joint venture. Recent capital actions include June 2026 registered direct offerings totaling 722,874 shares of common stock with accompanying five‑year PIPE warrants, aggregate gross proceeds of about $4.15 million, and an amended EUR 10,000,000 credit facility with an associated warrant for up to 1,850,000 shares at $1.00 per share.
Nexentis Technologies Inc. is registering 410,998 shares of common stock. The company is offering 410,998 shares at $7.056 per share in a registered direct placement, with aggregate gross proceeds to the company of $2,900,001.88. In a concurrent private placement to the same investors, Nexentis is issuing unregistered warrants to purchase up to 410,998 shares at an exercise price of $7.056 per share, exercisable immediately and expiring five years after issuance. The prospectus states net proceeds will be used for general corporate purposes and working capital. Shares outstanding used to calculate post-offering figures were 1,042,335 as of June 22, 2026, and delivery was expected on or about June 23, 2026.
Nexentis Technologies Inc. agreed to raise capital through a registered direct offering and concurrent private placement. The company will sell 410,998 shares of common stock at $7.056 per share, a premium to the Nasdaq Minimum Price, and issue 410,998 five-year warrants with the same exercise price.
The transactions are expected to generate approximately $2.9 million in gross proceeds, before expenses, and are scheduled to close on or about June 24, 2026, subject to customary conditions. Nexentis must file a resale registration statement for the warrant shares within 30 days of closing and have it declared effective within 60 days.